ERBB2 and breast neoplasm: Breast tumors that don’t express the estrogen (ER), progesterone (PR), and Her2 receptors (ER-/PR-/Her2-), termed triple negative (TNBC), are challenging to treat successfully because therapies such as Tamoxifen and Herceptin that target ER and Her2 signaling, respectively, are not effective.